Skip to Main content Skip to Navigation
Journal articles

Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients

Complete list of metadatas

https://hal.univ-lorraine.fr/hal-02510373
Contributor : Philippe de Carvalho <>
Submitted on : Tuesday, March 17, 2020 - 5:13:58 PM
Last modification on : Wednesday, March 18, 2020 - 1:16:40 AM

Identifiers

Citation

Patrick Rossignol, Joao Pedro Ferreira. Balancing Benefits and Risks of Spironolactone in HFpEF and Chronic Kidney Disease Patients. JACC: Heart Failure, Elsevier/American College of Cardiology, 2019, 7 (1), pp.33-35. ⟨10.1016/j.jchf.2018.11.016⟩. ⟨hal-02510373⟩

Share

Metrics

Record views

34